OncoMatch/Clinical Trials/NCT06484361

PET/MRI to Stage Prostate Cancer Patients

Is NCT06484361 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including 68Ga-PSMA and 68Ga-RM2 for prostate cancer.

Phase 2RecruitingIRCCS San RaffaeleNCT06484361Data as of May 2026

Treatment: 68Ga-PSMA · 68Ga-RM2 — The main goal of this phase II clinical trial is to define a novel approach of staging prostate cancer (PCa) patients by using a fully integrated positron emission tomography/ magnetic resonance imaging (PET/MRI) system with 68Ga-prostate specifica membrane antigen (PSMA) and 68Ga-RM2 (bombesin antagonist). 50 patients with biopsy proven PCa will be studied by PET/MRI with 68Ga-PSMA and with 68Ga-RM2 and then will undergo prostatectomy and pelvic lymphadenectomy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Grade: high

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify